ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO233

Renal and Cardiovascular (CV) Outcomes of Canagliflozin (CANA) According to Race and Ethnicity: A CREDENCE Secondary Analysis

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Levin, Adeera, University of British Columbia, Vancouver, British Columbia, Canada
  • Mahaffey, Kenneth W., Stanford University School of Medicine, Stanford, California, United States
  • Baldassarre, James S., Janssen Research & Development, LLC, Raritan, New Jersey, United States
  • Chu, Pei-Ling, Janssen Research & Development, LLC, Raritan, New Jersey, United States
  • de Zeeuw, Dick, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
  • L Heerspink, Hiddo Jan, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
  • Kavalam, Mary, Janssen Research & Development, LLC, Raritan, New Jersey, United States
  • Pollock, Carol A., Sydney Medical School, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia
  • Sun, Tao, Janssen Research & Development, LLC, Raritan, New Jersey, United States
  • Zinman, Bernard, Mt Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
  • Perkovic, Vlado, The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia
  • Bakris, George L., University of Chicago Medicine, Chicago, Illinois, United States
Background

CANA reduces kidney failure and CV events in people with type 2 diabetes who have chronic kidney disease. Given the international scope of the CREDENCE study, we assessed the efficacy of CANA according to self-reported race and ethnicity.

Methods

4401 participants with eGFR 30-<90mL/min/1.73m2 and urinary albumin:creatinine ratio >300-5000mg/g were randomized to CANA 100mg daily or matching placebo. Outcomes were analyzed in prespecified analyses by race and ethnicity, and results are reported without adjustment for multiplicity.

Results

The cohort enrolled were racially and ethnically diverse (n=2931 [67%] White, n=224 [5%] Black or African American, n=877 [20%] Asian, n=369 [8%] Other race, n=1423 [32%] Hispanic/Latino, n=2978 [68%] Non Hispanic/Latino [including not reported/unknown ethnicity]). CANA reduced the primary outcome of end-stage kidney disease (ESKD), sustained doubling serum creatinine (dSCr), or renal or CV death overall, with no evidence the effect differed in racial (P interaction=0.91) and ethnic subgroups (P interaction=0.31; Figure). Similarly, CANA reduced CV outcomes and the renal composite of ESKD, sustained dSCr or renal death, with no differences among the different racial and ethnic groups (all P interaction≥0.06).

Conclusion

CANA reduces the incidence of renal and CV events in people with type 2 diabetes and substantial albuminuria, with no evidence that effects differ in racial or ethnic groups, thereby supporting the breadth of use across a diverse group of patients.

Funding

  • Commercial Support